[CERS] Cerus Corporation


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.66 Change: 0.26 (5.91%)
Ext. hours: Change: 0 (0%)

chart CERS

Refresh chart

Strongest Trends Summary For CERS

CERS is in the medium-term down -16% in 2 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company?s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for tran

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -10.57% Sales Growth - Q/Q-19.77% P/E-3.54
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-33.51% ROE-43.65% ROI-39.88%
Current Ratio5.99 Quick Ratio5.29 Long Term Debt/Equity0.08 Debt Ratio0.21
Gross Margin40% Operating Margin-137.01% Net Profit Margin-132.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities76.5 M Cash From Investing Activities-65.59 M Cash From Operating Activities-15.75 M Gross Profit2.98 M
Net Profit-9.46 M Operating Profit-14.37 M Total Assets143.22 M Total Current Assets136.42 M
Total Current Liabilities22.76 M Total Debt9.88 M Total Liabilities33.29 M Total Revenue7.69 M
Technical Data
High 52 week7.02 Low 52 week4.3 Last close4.51 Last change4.88%
RSI33.52 Average true range0.23 Beta0.97 Volume739.37 K
Simple moving average 20 days-6.56% Simple moving average 50 days-11.42% Simple moving average 200 days-19.25%
Performance Data
Performance Week1.35% Performance Month-16.17% Performance Quart-19.18% Performance Half-26.07%
Performance Year-24.71% Performance Year-to-date-11.05% Volatility daily2.91% Volatility weekly6.51%
Volatility monthly13.35% Volatility yearly46.23% Relative Volume436.07% Average Volume872.48 K
New High New Low


2019-11-13 08:30:00 | Cerus Corporation to Present at the Stifel 2019 Healthcare Conference

2019-11-12 06:45:12 | How Should Investors React To Cerus Corporation's NASDAQ:CERS CEO Pay?

2019-11-08 08:30:00 | Cerus Corporation to Present at the Stephens Nashville Investment Conference

2019-11-01 09:34:11 | Were Hedge Funds Right About Cashing Out Of Cerus Corporation CERS?

2019-11-01 07:38:56 | The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

2019-10-31 12:41:23 | Edited Transcript of CERS earnings conference call or presentation 30-Oct-19 8:30pm GMT

2019-10-30 18:45:10 | Cerus CERS Reports Q3 Loss, Tops Revenue Estimates

2019-10-30 16:01:00 | Cerus Corporation Announces Third Quarter 2019 Results

2019-10-23 10:34:02 | Will Cerus CERS Report Negative Earnings Next Week? What You Should Know

2019-10-21 08:30:00 | Cerus Corporation to Release Third Quarter 2019 Results and to Discuss Recent FDA Guidance for Bacterial Safety of Platelets on October 30, 2019

2019-10-18 08:30:00 | Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting

2019-10-13 09:36:37 | How Much Are Cerus Corporation NASDAQ:CERS Insiders Taking Off The Table?

2019-09-30 12:00:00 | Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion

2019-09-27 08:30:00 | Cerus Corporation to Present at the 2019 Cantor Global Healthcare Conference

2019-09-13 07:05:17 | Did You Miss Cerus's NASDAQ:CERS 32% Share Price Gain?

2019-08-28 08:30:00 | Cerus Corporation to Participate in Upcoming Investor Conferences

2019-08-14 09:44:56 | What Kind Of Shareholder Appears On The Cerus Corporation's NASDAQ:CERS Shareholder Register?

2019-08-05 13:14:33 | Edited Transcript of CERS earnings conference call or presentation 1-Aug-19 8:30pm GMT

2019-08-01 21:24:03 | Cerus Corporation CERS Q2 2019 Earnings Call Transcript

2019-08-01 18:35:10 | Cerus CERS Reports Q2 Loss, Tops Revenue Estimates

2019-08-01 16:01:00 | Cerus Corporation Announces Record Second Quarter 2019 Results

2019-07-25 10:34:02 | Analysts Estimate Cerus CERS to Report a Decline in Earnings: What to Look Out for

2019-07-22 08:30:00 | Cerus Corporation to Release Second Quarter 2019 Results on August 1, 2019

2019-07-08 11:54:42 | Cerus Corporation NASDAQ:CERS: Time For A Financial Health Check

2019-07-05 16:39:44 | Here’s What Hedge Funds Think About Cerus Corporation CERS

2019-06-24 18:00:00 | Cerus Corporation Announces Presentations Highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT

2019-06-04 14:16:08 | How Cerus Corporation NASDAQ:CERS Can Impact Your Portfolio Volatility

2019-06-03 08:30:00 | Cerus Corporation Announces New Corporate Brand and Global Headquarters

2019-05-14 08:44:00 | Cerus’ INTERCEPT Blood System Provides Alternative to Year-Round Babesia Testing in Latest FDA Guidance Document

2019-05-08 17:39:10 | Edited Transcript of CERS earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-07 20:23:52 | Cerus Corporation CERS Q1 2019 Earnings Call Transcript

2019-05-07 19:25:11 | Cerus CERS Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 18:18:46 | Cerus: 1Q Earnings Snapshot

2019-05-07 16:05:00 | Cerus Corporation Announces Record First Quarter 2019 Results

2019-05-07 10:53:45 | Here’s What Hedge Funds Think About Cerus Corporation CERS

2019-04-30 10:32:02 | Analysts Estimate Cerus CERS to Report a Decline in Earnings: What to Look Out for

2019-04-25 08:30:00 | Cerus Corporation to Release First Quarter 2019 Results on May 7, 2019

2019-04-24 11:48:58 | Cerus Corporation NASDAQ:CERS Insiders Have Been Selling

2019-04-01 16:05:00 | Cerus Corporation Strengthens Balance Sheet with an Expandable Debt Facility of up to $90 Million

2019-03-05 16:15:00 | Cerus Corporation Announces Appointment of Jami Nachtsheim to Board of Directors

2019-02-27 16:09:11 | Edited Transcript of CERS earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 23:02:34 | Cerus Corporation CERS Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:02:00 | Cerus Corporation Announces Record Fourth Quarter and Full Year 2018 Results

2019-02-22 08:30:00 | Cerus to Participate In Upcoming Investor Conferences

2019-02-21 11:20:20 | How Much Of Cerus Corporation NASDAQ:CERS Do Institutions Own?

2019-02-14 07:20:00 | Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America — Fundamental Analysis, Key Performance Indications

2019-02-13 08:30:00 | Cerus to Release Fourth Quarter and Full Year 2018 Results on February 26, 2019

2019-01-16 11:00:17 | How Should Investors React To Cerus Corporation’s NASDAQ:CERS CEO Pay?

2019-01-07 08:30:00 | Cerus Announces Preliminary Fourth Quarter and Full Year 2018 Product Revenue

2019-01-04 08:30:00 | William Moore Appointed as Cerus Corporation’s Senior Vice President of Manufacturing Operations and Supply Chain